Last updated: 11/02/2018 23:31:10
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS)
Trial description: Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Number of participants with adverse event (AE) of nausea during the first 3 weeks fixed dose titration of ropinirole IR and ropinirole CR- RLS
Timeframe: Baseline (Day 0) up to Week 3
Secondary outcomes:
Number of participants with mild, moderate and severe nausea during the first 3 weeks fixed dose titration of ropinirole CR- RLS and ropinirole IR
Timeframe: Baseline (Day 0) to Week 3
Number of participants with most common AE (reported by 10 % or more of participants from either treatment group) during the first 3 weeks fixed dose titration of ropinirole IR and ropinirole CR- RLS
Timeframe: Baseline (Day 0) up to Week 3
Number of participants with the mild, moderate and severe most common AE (reported by 10% or more of participants from either treatment group) during the first 3 weeks fixed dose titration of ropinirole IR and ropinirole CR- RLS
Timeframe: Baseline (Day 0) up to Week 3
Number of participants with AE during the entire 12 week on treatment phase
Timeframe: Baseline (Day 0) up to Week 12
Number of participants with mild, moderate and severe AE during the entire 12 week on treatment phase
Timeframe: Baseline (Day 0) up to Week 12
Number of participants with dose reductions due to lack of tolerability between Weeks 3 and 12
Timeframe: Week 3 to Week 12
Number of participants with withdrawals due to lack of tolerability during the first 3 weeks fixed dose titration, and during the entire 12 week on treatment phase
Timeframe: Baseline (Day 0) up to Week 12
Number of participants with withdrawals due to insufficient therapeutic effect during the entire 12 week on treatment phase
Timeframe: Baseline (Day 0) up to Week 12
Mean change from Baseline in number of h of RLS symptoms during the evening, and during the evening and night time at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in number of h of RLS symptoms that were either absent or of maximal severity of mild during the evening, and during the evening and night time at Week 12
Timeframe: Baseline (Day 0) and Week 12
Percentage of treated days, which were RLS symptom-free
Timeframe: Baseline (Randomization, Day 0) up to Week 12
Median time to onset of the first 4 consecutive days that were completely RLS symptom-free within the first 4 weeks of the treatment phase
Timeframe: Baseline (Randomization, Day 0) up to Week 4
Mean change from Baseline in the International RLS (IRLS) Rating Scale total score at Weeks 1, 2, 3, 4, 8, and 12 for observed cases (OC)
Timeframe: Baseline (Day 0) up to Week 12
Mean change from Baseline in the IRLS Rating Scale total score at Weeks 12 LOCF
Timeframe: Baseline (Day 0) and Week 12
Number of participants with a score of Much improved (2) or Very much improved (1) on the CGI-I scale between Week 1 and Week 12 (OC)
Timeframe: Week 1 to Week 12
Number of participants with a score of Much improved (2) or Very much improved (1) on CGI-I scale at Week 12 (LOCF)
Timeframe: Week 12
Median time to response on the CGI-I scale
Timeframe: Baseline (Day 0) to Week 12
Mean change from Baseline in the Sleep Disturbance Domain of the 12-item Medical Outcomes Study (MOS-12) Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the Sleep Quantity Domain of the MOS-12 Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the Sleep Adequacy Domain of the MOS-12 Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the Somnolence Domain of the MOS-12 Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the Sleep Problems Index I of the MOS-12 Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the Sleep Problems Index II of the MOS-12 Sleep Scale at Week 12
Timeframe: Baseline (Day 0) and Week 12
Mean change from Baseline in the overall life impact score of the Johns Hopkins RLS Quality of Life Questionnaire at Week 12
Timeframe: Baseline (Day 0) and Week 12
Interventions:
Drug: ropinirole Extended Release (XR)
Enrollment:
563
Observational study model:
Not applicable
Primary completion date:
2006-15-12
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Restless Legs Syndrome
Product
ropinirole
Collaborators
Not applicable
Study date(s)
February 2006 to December 2006
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18 - 79 years
Accepts healthy volunteers
No
- Diagnosis of primary RLS according to RLS Diagnostic Clinical Interview and International Restless Legs Syndrome Study Group Diagnostic Criteria.
- Disturbed sleep, with both evening (between 5:00 pm and 8:00 pm) and night time (between 8:00 pm and 8:00 am) symptoms requiring treatment.
- Signs of secondary RLS.
- Primary sleep disorder or movement disorder other than RLS.
Inclusion and exclusion criteria
Inclusion criteria:
- Diagnosis of primary RLS according to RLS Diagnostic Clinical Interview and International Restless Legs Syndrome Study Group Diagnostic Criteria.
- Disturbed sleep, with both evening (between 5:00 pm and 8:00 pm) and night time (between 8:00 pm and 8:00 am) symptoms requiring treatment.
Exclusion criteria:
- Signs of secondary RLS.
- Primary sleep disorder or movement disorder other than RLS.
- Unstable medical conditions.
- Inability to tolerate dopamine agonists or dopamine antagonists.
- Unwilling to discontinue any medications currently being taken to treat RLS symptoms.
Trial location(s)
Location
GSK Investigational Site
Redondo Beach, California, United States, 90277
Status
Study Complete
Location
GSK Investigational Site
West Yarmouth, Massachusetts, United States, 02673
Status
Study Complete
Location
GSK Investigational Site
Winnetka, California, United States, 91306
Status
Study Complete
Location
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19053
Status
Study Complete
Location
GSK Investigational Site
Frome, Somerset, United Kingdom, BA11 1EZ
Status
Study Complete
Location
GSK Investigational Site
Trowbridge, Wiltshire, United Kingdom, BA14 9AR
Status
Study Complete
Location
GSK Investigational Site
Burlingame, California, United States, 94010
Status
Study Complete
Location
GSK Investigational Site
Camperdown, New South Wales, Australia, 2050
Status
Study Complete
Location
GSK Investigational Site
Auchenflower, Queensland, Australia, 4066
Status
Study Complete
Location
GSK Investigational Site
ROELOFARENDSVEEN, Netherlands, 2371 RB
Status
Study Complete
Location
GSK Investigational Site
Chesterfield, Derbyshire, United Kingdom, S40 4TF
Status
Study Complete
Location
GSK Investigational Site
Sun City, Arizona, United States, 85351
Status
Study Complete
Location
GSK Investigational Site
Pasadena, California, United States, 91106
Status
Study Complete
Location
GSK Investigational Site
Springfield, Massachusetts, United States, 01104
Status
Study Complete
Location
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
Status
Study Complete
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85050
Status
Study Complete
Location
GSK Investigational Site
Boca Raton, Florida, United States, 33486
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
Status
Study Complete
Location
GSK Investigational Site
Kalamazoo, Michigan, United States, 49048
Status
Study Complete
Location
GSK Investigational Site
St. Paul, Minnesota, United States, 55101
Status
Study Complete
Location
GSK Investigational Site
Newport Beach, California, United States, 92660
Status
Study Complete
Location
GSK Investigational Site
Long Beach, California, United States, 90806
Status
Study Complete
Location
GSK Investigational Site
Warwick, Rhode Island, United States, 02886
Status
Study Complete
Location
GSK Investigational Site
Albany, New York, United States, 12205
Status
Study Complete
Location
GSK Investigational Site
Fargo, North Dakota, United States, 58104
Status
Study Complete
Location
GSK Investigational Site
Coventry, Warwickshire, United Kingdom, CV6 4DD
Status
Study Complete
Location
GSK Investigational Site
Koethen, Sachsen-Anhalt, Germany, 06366
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
Status
Study Complete
Location
GSK Investigational Site
Worcester, Massachusetts, United States, 01655
Status
Study Complete
Location
GSK Investigational Site
Anaheim, California, United States, 92801
Status
Study Complete
Location
GSK Investigational Site
Burlington, Vermont, United States, 05401
Status
Study Complete
Location
GSK Investigational Site
Stanford, California, United States, 94305-5548
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35209
Status
Study Complete
Location
GSK Investigational Site
Santa Monica, California, United States, 90404
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89119
Status
Study Complete
Location
GSK Investigational Site
Blackpool, Lancashire, United Kingdom, FY4 3AD
Status
Study Complete
Location
GSK Investigational Site
Coeur D'Alene, Idaho, United States, 83814
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63128
Status
Terminated/Withdrawn
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2006-15-12
Actual study completion date
2006-15-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website